Zydus Cadila settles DELZICOL (Mesalamine) patent litigation

Likely to market generic version of DELZICOL in US in early March 2017

Zydus Cadila announced that the patent litigation relating to Allergen's DELZICOL (Mesalamine) has been settled. As a results of the settlement, and if approved by FDA, its subsidiary, Zydus Pharmaceuticals (USA) Inc. will be able to market its generic version of DELZICOL in the United States beginning on 01 March 2017 or earlier under certain circumstances.

Powered by Capital Market - Live News